

MarÃ±a BuÃ±uales

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6983547/publications.pdf>

Version: 2024-02-01

21
papers

555
citations

623734

14
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

806
citing authors

#	ARTICLE	IF	CITATIONS
1	Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 23-33.	4.4	2
2	Adenovirus-Mediated Inducible Expression of a PD-L1 Blocking Antibody in Combination with Macrophage Depletion Improves Survival in a Mouse Model of Peritoneal Carcinomatosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4176.	4.1	6
3	Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 25, 585-602.	5.1	16
4	Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 22, 210-221.	4.1	6
5	Epilepsy and neuropsychiatric comorbidities in mice carrying a recurrent Dravet syndrome SCN1A missense mutation. <i>Scientific Reports</i> , 2019, 9, 14172.	3.3	61
6	Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses. <i>Molecular Therapy</i> , 2019, 27, 1892-1905.	8.2	28
7	Inhibition of adenovirus infection by mifepristone. <i>Antiviral Research</i> , 2018, 159, 77-83.	4.1	20
8	Adaptation of vectors and drug-inducible systems for controlled expression of transgenes in the tumor microenvironment. <i>Journal of Controlled Release</i> , 2017, 268, 247-258.	9.9	9
9	A Versatile Vector for In Vivo Monitoring of Type I Interferon Induction and Signaling. <i>PLoS ONE</i> , 2016, 11, e0152031.	2.5	6
10	Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model. <i>Molecular Cancer</i> , 2015, 14, 210.	19.2	14
11	Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver. <i>Liver International</i> , 2015, 35, 1274-1289.	3.9	16
12	Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model. <i>Gene Therapy</i> , 2015, 22, 696-706.	4.5	36
13	Evaluation of Monocytes as Carriers for Armed Oncolytic Adenoviruses in Murine and Syrian Hamster Models of Cancer. <i>Human Gene Therapy</i> , 2012, 23, 1258-1268.	2.7	19
14	Self-inactivating helper virus for the production of high-capacity adenoviral vectors. <i>Gene Therapy</i> , 2011, 18, 1025-1033.	4.5	23
15	Efficient gene delivery by EGF-lipoplexes <i>in vitro</i> and <i>in vivo</i> . <i>Nanomedicine</i> , 2011, 6, 89-98.	3.3	27
16	Treatment of Pancreatic Cancer With an Oncolytic Adenovirus Expressing Interleukin-12 in Syrian Hamsters. <i>Molecular Therapy</i> , 2009, 17, 614-622.	8.2	84
17	Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters. <i>Cancer Gene Therapy</i> , 2009, 16, 703-712.	4.6	25
18	Characterization of cisplatin cytotoxicity delivered from PLGA-systems. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 68, 503-512.	4.3	36

#	ARTICLE	IF	CITATIONS
19	Human Adenovirus Replicates in Immunocompetent Models of Pancreatic Cancer in Syrian Hamsters. Human Gene Therapy, 2007, 18, 681-690.	2.7	29
20	Serum-resistant lipopolyplexes for gene delivery to liver tumour cells. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 58-66.	4.3	70
21	Antitumoral activity of transferrin-lipoplexes carrying the IL-12 gene in the treatment of colon cancer. Journal of Drug Targeting, 2006, 14, 527-535.	4.4	22